Search academic texts

Information × Registration Number 0220U001118, 0119U002051 , R & D reports Title Identifying factors for long-term survival in patients with multiple myeloma in conditions of modern therapy and developing management strategy for these patients after achieving treatment response. popup.stage_title Head Maslyak Zvenyslava Volodymyrovna, Registration Date 27-01-2020 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 The results of examinations and treatment of 53 patients with multiple myeloma (MM) are presented in the work, with 2 of them having the disease starting with dormant multiple myeloma (SMM) and 1 - with monoclonal gammopathy of unexplained genesis (MGUS) aged from 32 to 77 years. . Patients were administered immunomodulators or bortezomib in the first and second line of therapy. The use of bortezomib in the first or subsequent lines of treatment in patients with MM has shown its high efficiency with minimal toxicity. Median survival in patients with MM was not achieved with bortezomib in both the first and second treatment lines. A statistically significant difference in survival was found between patients receiving immunomodulators in the first or second line of treatment, compared with patients treated with bortezomib-containing regimens in both the first and second line of treatment. Thalidomide in combination PCT regimens resulted in a high frequency of good response to treatment in patients with MM in the first line of therapy. In the second line, a better response was observed when bortezomib was administered by increasing the frequency of a very good response to treatment. The duration of overall survival in patients with multiple myeloma depends on the gender, women live longer than men. At the same time, no statistically significant difference in patient survival was found, depending on age, immunoglobulin heavy chain class, light chain type, ISS stage. Carrying an auto-PBSCT significantly improves the overall response to treatment in multiple myeloma patients. Product Description popup.authors Виговська Ярослава Іллівна Городиська Тетяна Омелянівна Залокоцька Леся Володимирівна Лукавецький Лесь Миронович Масляк Звенислава Володимирівна Мельник Марія Іллярівна Пеленьо Наталія Володимирівна Приставська Христина Богданівна Тхір Христина Романівна Цяпка Орест Миколайович popup.nrat_date 2020-04-02 Close